Replies to post #216308 on Avid Bioservices Inc (CDMO)

[Protector]

PPHM UP 5% (1.48$) in Pre-Market on 25K volume.

Next BIGGEST block in Level 3 waiting at 1.75$ (60K shares).

Levels between 1.48$ till 1.75$ around or below 5K shares with 16K shares exception at 1.51$.

ATTENTION: This 1.48$ could be a HEAD FAKE! The Bid content does not show signs of an expected run up. More like someone wanted to pump PPHM to 1.48$ possibly to short in it at open.

Will need to see.

[hutschi]

• 21-Apr-2015 14:11 - PEREGRINE PHARMACEUTICALS - SHARES UP 4.96 PCT AT $1.48 PREMARKET AFTER CO'S PHOSPHATIDYLSERINE SHOWS ANTI-TUMOR EFFECTS IN PRECLINICAL DATA
PEREGRINE PHARMACEUTICALS - SHARES UP 4.96 PCT AT $1.48 PREMARKET AFTER CO'S PHOSPHATIDYLSERINE SHOWS ANTI-TUMOR EFFECTS IN PRECLINICAL DATA PPHM.O - RTRS

[hutschi]

Peregrine Pharmaceuticals Inc data presented at AACR demonstrate synergistic anti-tumor effects of peregrine pharmaceuticals' phosphatidylserine (PS) PPHM.OQ - RINB
21-Apr-2015 14:11
Peregrine Pharmaceuticals Inc:
• Says presentation of data from preclinical studies demonstrating combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors promoted strong, localized and enhanced efficacy in models of melanoma and breast cancer
• Says these data were presented at 106th Annual Meeting of the American Association for Cancer Research (AACR) being held in Philadelphia, Pennsylvania from April 18-22, 2015
• Says Peregrine's lead PS-blocking antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) in Phase III clinical trial named Sunrise